Figure 3

Combination therapy promotes effector CD44⁺ CD8⁺ PD1^- and decreased terminally-differentiated CD103⁺ KLRG-1⁺ T-regulatory cells. Mice were inoculated with Pan02 tumors as indicated in Fig. 1a, and tumors and TDLNs were collected as previously shown. (a) Bar graphs show the percentage of CD44⁺ CD8⁺ CD3⁺ cells on the injected and contralateral sides. (b) Representative histograms show CD44⁺ expression on CD8⁺ CD3⁺ PD-1⁻ cells on the injected and contralateral sides. (c) Bar graphs show the percentage of CD44⁺ PD-1⁻ CD8⁺ CD3⁺ cells on the injected and contralateral sides. (d) Bar graphs show the percentage of CD69⁺ CD8⁺ CD3⁺ cells on the injected and contralateral sides. (e) Representative histograms show CD69⁺ expression on CD8⁺ CD3⁺ PD-1⁻ cells on the injected and contralateral sides. (f) Bar graphs show the percentage of CD69⁺ PD-1⁻ CD8⁺ CD3⁺ cells on the injected and contralateral sides. (g) A representative dot plot shows CD103⁺ KLRG-1⁺ expression on CD4⁺ CD25⁺ FOXP3⁺ tumor-infiltrating T-reg cells on the injected and contralateral sides. (h) Bar graphs show the percentage of CD103⁺ KLRG-1⁺ expression on CD4⁺ CD25⁺ FOXP3⁺ tumor-infiltrating T-reg cells on the injected and contralateral sides. Data are presented as mean ± SD (n = 4 mice). This experiment was conducted at least two times. One-way ANOVA with a post-hoc Tukey’s tests was performed. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.